|
|
 |
|
| Description |
| PD0325901 is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. PD0325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation1,2. |
| Disclaimer |
| This Stemgent® Product is exclusively distributed by Miltenyi Biotec outside the USA and Israel. |
| Specifications and technical documents |
| Specification SheetsMaterial Safety Data Sheets
|
| |
|
| Figure 1 |
 |
|
| Figure 2 |
 |
|
| Figure 3 |
| Stemolecule™ PD0325901 chemical structure. |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| Stemolecule PD0325901 |
- 2 mg
- Stemgent Catalog # 04-0006
130-095-557
|
|
| References |
| 1. Bain et al. (2007) Biochem. J. 408: 297–315. |
| 2. Sebolt-Leopold and Herrera (2004) Nature Rev. Cancer 4: 937–947. |
| 3. Lin et al. (2009) Nat. Methods 6: 805-808. |
|
| MACS Stem Cell newsletter |
|
Stay current with important developments in stem cell research by subscribing to
Stem Cell Updates.
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
